✕

Aktion bei finanzen.net ZERO

Von den Profis lernen. Beim Kostensieger handeln.

Eröffne jetzt dein Depot bei unserem Broker finanzen.net ZERO – und lies 3 Monate kostenfrei das Fachmagazin der Börsenexperten, die NVIDIA schon vor einem Jahrzehnt auf der Kaufliste hatten.

Handle deine Aktien beim Kostensieger der Stiftung Warentest (12/2025)

Entdecke mit dem aktien-Magazin chancenreiche Titel, bevor der Mainstream sie kennt (Wert: 147 €)

Sichere dir zusätzlich 50 € Neukundenbonus direkt auf dein Cash-Konto

Jetzt kostenlos starten

Aktion bis 31.07.2026. Es gelten die Teilnahmebedingungen.

Nicht mehr anzeigen

Iovance Biotherapeutics Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

3,81 EUR +0,35 EUR +10,12 %

19:33:57

STU

4,44 USD +0,50 USD +12,71 %

19:54:53

BTT

Iovance Biotherapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Smartphone

Marktkap.1,58 Mrd. EUR

Div. Rendite0,00%

WKNA2DT49

ISINUS4622601007

SymbolIOVA

Iovance Biotherapeutics Aktien News

Sortieren:Datum Meistgelesen

14.07.25PR NewswireLost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

14.07.25PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

13.07.25PR NewswireIOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit

WerbungIovance Biotherapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

12.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA

07.07.25PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

02.07.25PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

27.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

24.06.25PR NewswireIovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

22.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

17.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

16.06.25PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

13.06.25PR NewswireIOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

13.06.25PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

12.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

01.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

28.05.25PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

28.05.25PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit

23.05.25PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

20.05.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

19.05.25PR NewswireIOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

19.05.25PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit

23.01.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

14.01.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

06.01.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

28.12.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

Iovance Biotherapeutics News

Iovance Biotherapeutics News: auf dieser Seite finden Sie alle Iovance Biotherapeutics News und Nachrichten zur Iovance Biotherapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Iovance Biotherapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Iovance Biotherapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.